0000-0002-9099-420X About
Dr. Subhash Thuluva is a global clinical development leader with over two decades of experience in advancing investigational products and vaccines from early development to market authorization and WHO prequalification. He has played a pivotal role in the development, licensure, and global deployment of more than 18 vaccines, several of which are integral to India’s Universal Immunization Program (UIP) and are WHO-prequalified for global use.
Currently serving as Senior Vice President & Head – Global Clinical Development at Biological E, Dr. Thuluva provides strategic and operational leadership for the clinical development of novel vaccines and lifecycle management of marketed products. His leadership spans all aspects of vaccine development from clinical strategy, protocol design, and regulatory submissions to safety assessment and global collaborations. He has been instrumental in achieving market authorization and WHO prequalification for major vaccines, including Measles-Rubella, Typhoid Conjugate, Hepatitis B, Pentavalent (DTwP-HBV-Hib), and Pneumococcal Conjugate (14-valent), as well as in the development of the COVID-19 vaccine CORBEVAX™, which achieved WHO Emergency Use Listing with over 98 million doses administered.
Dr. Thuluva has led over 100 clinical studies and guided global teams across India, Europe, the USA, South Africa, and China, coordinating with major regulatory authorities including USFDA, EMA, WHO, MHRA, ANVISA, and DCGI. His leadership has been central to advancing new-generation vaccines currently in the pipeline including PCV-24, IPV, Hexavalent, Oral Cholera, Meningococcal, Yellow Fever, and HPV vaccines.
A prolific scientific contributor, he has authored 21 peer-reviewed publications in high-impact journals and is frequently featured in leading media outlets and scientific platforms. Dr. Thuluva’s career exemplifies strategic innovation and global impact in vaccine clinical development, driving public health outcomes through scientific excellence, regulatory expertise, and collaborative leadership.
Employment
-
Biological E (India) Senior Vice President & Head – Global Clinical Development2017 - Present
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (25)
- Safety, Immunogenicity of Co-Administered Vaccines, and Lot-to-Lot Consistency of a 14-Valent Pneumococcal Conjugate Vaccine (PNEUBEVAX 14®) Administered at 6–10–14 Weeks in Healthy Infants: A Multicenter, Phase IV Trial Save
- Immunogenicity and Safety of Biological E’s Monovalent rDNA Hepatitis B Vaccine (BEVAC®) in Neonates and Infants: A Multicentre, Randomized, Phase IV Non-Inferiority Trial Save
- Safety and immunogenicity of a 14-valent pneumococcal conjugate vaccine (BE-PCV14) administered in a 3p + 1 schedule to healthy Indian infants and toddlers: a prospective, multicenter, active-controlled phase IV trial Save
- Safety and Immunogenicity of Biological E’s 14-valent Pneumococcal Conjugate Vaccine (PNEUBEVAX 14 ® ) Administered in a 3p+1 Schedule to Healthy Indian Infants and Toddlers: A Prospective, Multicenter, Active Controll… Save
- Beyond immunogenicity in XBB.1.5 subunit COVID-19 boosters focusing on durability, dosing, and target populations: authors reply Save
- Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD™ or COVAXIN: A Prospective double-blind randomised phase III clinical study Save
- Safety and immunogenicity of booster doses of an XBB.1.5 RBD subunit COVID-19 vaccine among individuals aged 5–80 years in India: a phase 3, single-blind, randomised controlled trial Save
- Safety and immunogenicity of Biological E's typhoid conjugate vaccine TYPHIBEVⓇ concomitantly administered with measles rubella vaccine: a phase IV prospective, multicenter study Save
- A multi-centre, single arm, Phase-III study to assess the safety and reactogenicity of biological E's Vi-capsular polysaccharide-CRM197 conjugate typhoid vaccine in ≥6 months old infants to ≤45 years old adults. Save
- Immunogenicity and safety of a multi-human dose formulation of Biological E’s 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14®) administered to 6–8-week-old healthy infants: a phase 3, single-blind, randomized, active-controlled stu… Save